| 名稱 | CPI-169 racemate |
| 描述 | CPI-169 racemate (CPI 169) is a potent, and selective EZH2 inhibitor with IC50 of 0.24 nM, 0.51 nM, and 6.1 nM for EZH2 WT, EZH2 Y641N, and EZH1, respectively. |
| 細(xì)胞實驗 | Relative cell numbers are assessed by Cell Titer-Glo (CTG) luminescent cell viability assay using an Envision instrument. GraphPad Prism 6.0 is used for curve fitting, IC50/GI50 and Hill coefficient (H) calculations. The GI90 is calculated using the formula: EC90 = (90 /100-90)1/H * EC50.(Only for Reference) |
| 激酶實驗 | Biochemical Assays: Compound potency is also assessed through incorporation of 3H-SAM into a biotinylated H3 peptide. Specifically, PRC2 containing either EZH1 (160 pM), wt EZH2 (40 pM), or Y641N mutant EZH2 (80 pM, both EZH2 prepared in-house) is pre-incubated with 3H-SAM (0.9 μM), 2 μM H3K27me3 activating peptide (H2N-RKQLATKAAR(Kme3)SAPATGGVKKP-amide) and compounds (as 10 point duplicate dose response titrations) for 120 min in a buffer consisting of 50 mM Tris (pH 8.5), 1 mM DTT, 0.07 mM Brij-35, 0.1% BSA, and 0.8% DMSO in a total volume of 12.5 μl in a black 384 well plate. Reaction is initiated with biotinylated H3 substrate peptides (H3K27me1 for wt EZH2, H3K27me2 for Y641N mutant EZH2; H2N-RKQLATKAAR(Kmen)SAPATGGVKKP-NTPEGBiot) as a 2 μM stock in 12.5 μL and allowed to react at room temperature for 5 h. Quenching is accomplished by addition of 20 μl of STOP solution (50 mM Tris (pH 8.5), 200 mM EDTA, 2 mM SAH). 35 μL of the quenched solution is transferred to Streptavidin Flashplates, incubated overnight, washed, and read in a TopCount Reader. For titrations all compound dilutions are in DMSO, final DMSO concentrations are 0.8% (v/v), and turnover is kept to less than < 5%. IC50s are calculated using non-linear least square four parameter fits (GraphPad 6.0). |
| 動物實驗 | Animal Models: Mice bearing KARPAS-422 subcutaneous xenograftsFormulation: 10% DMSO + 60% polytheylene glycol 400 + 30% ddH2ODosages: 200 mg/kg, BIDAdministration: s.c. |
| 體外活性 | 在KARPAS-422細(xì)胞中，CPI-169呈劑量依賴性地抑制細(xì)胞活力，并在與ABT-199聯(lián)合使用時產(chǎn)生協(xié)同抗增殖活性。在25種NHL細(xì)胞系中的16種中，CPI-169還以GI50 <5 μM的效果抑制細(xì)胞生長。[1] |
| 體內(nèi)活性 | 在攜帶KARPAS-422異種移植瘤的小鼠中，CPI-169（200 mg/kg, s.c.）有效降低了H3K27me3的水平，并導(dǎo)致淋巴瘤腫瘤的退縮，同時未影響體重或引起任何明顯的不良反應(yīng)。[1] |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : 93 mg/mL (175.9 mM)
DMSO : 93 mg/mL (175.9 mM)
|
| 關(guān)鍵字 | CPI169 racemate | CPI 169 racemate | CPI-169 racemate |
| 相關(guān)產(chǎn)品 | Bisdemethoxycurcumin | dBET6 | 3-methyl-1,2,3,4-tetrahydroquinazolin-2-one | MRTX-1719 | CeMMEC1 | Tazemetostat | EPZ015666 | (+)-JQ-1 | Curcumin | Naphthol AS-E | ABBV-744 | Piribedil |
| 相關(guān)庫 | 抑制劑庫 | 抗癌活性化合物庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 | 染色質(zhì)修飾分子庫 | 抗衰老化合物庫 | 表觀遺傳庫 | 干細(xì)胞分化化合物庫 | 甲基化化合物庫 | 細(xì)胞重編程化合物庫 |